These results indicated that tRF-60:76-Val-AAC-1-M5 might target Tnfrsf10b and Bcl2l1 to influence the therapeutic heterogeneity of sacubitril/valsartan through the lipid and atherosclerosis signaling pathway. Here, BCL2L1 is linked to atherosclerosis.